A 2-Period Crossover Study of BPN14770 in Adults Males With Fragile X Syndrome
Status:
Completed
Trial end date:
2020-07-31
Target enrollment:
Participant gender:
Summary
This is a single-center, randomized, double-blind, 2-period crossover study to explore the
effects of BPN14770 on cognitive function and behavior in subjects with Fragile X Syndrome.
Subjects will receive both active treatment with BPN14770 capsules and matching placebo
capsules in the course of the study. One treatment will be administered during each of the
12-week study periods.